Skip to main content
Signal8

Hemogenyx Pharmaceuticals Plc (HOPHF)

Sector: Biotechnology

Industry: Biotechnology

Hemogenyx Pharmaceuticals Plc logo

Hemogenyx Pharmaceuticals Plc

OTC:HOPHFHealthcare
Mkt Cap$16.07M
EV-
Float3.88M
O/S6.9M
Inst Own-
SI<0.1%
Net Cash/Sh-
Dilution
Historical Data
DateOpenHighLowCloseVolume
Nov 10, 20262.332.332.332.3325,000
Nov 9, 20262.332.332.332.3325,000
Nov 6, 20262.332.332.332.3325,000
Nov 3, 20262.332.332.332.3325,000
Nov 2, 20262.332.332.332.3325,000
Oct 30, 20262.332.332.332.3325,000
Oct 29, 20262.332.332.332.3325,000
Oct 26, 20262.332.332.332.3325,000
Oct 23, 20262.332.332.332.3325,000
Oct 22, 20262.332.332.332.3325,000
Oct 19, 20262.332.332.332.3325,000
Oct 16, 20262.332.332.332.3325,000
Oct 15, 20262.332.332.332.3325,000
Oct 12, 20262.332.332.332.3325,000
Oct 9, 20262.332.332.332.3325,000
Oct 6, 20262.332.332.332.3325,000
Analyst Coverage
No analyst coverage for this companyNo ratings, price targets, or covering firms on file.
About

Hemogenyx Pharmaceuticals Plc is a preclinical-stage biotechnology firm dedicated to discovering, developing, and bringing to market innovative therapies for various blood-related diseases.

The company's pipeline includes several promising candidates tailored for the bone marrow/hematopoietic stem cell (BM/HSC) transplant market. These include a CDX bi-specific antibody designed to target relapsed/refractory acute myeloid leukemia (R/R AML), certain forms of acute lymphoblastic leukemia, and myelodysplastic syndrome. This novel approach seeks to condition patients for bone marrow transplants, offering a potential alternative to conventional chemotherapy and/or radiation treatments.

Additionally, Hemogenyx is advancing HEMO-CAR-T therapy, which utilizes chimeric antigen receptor T-cells to specifically identify and eradicate human AML-derived cells, demonstrated in both in vitro and in vivo studies.

Its portfolio also features Human Postnatal Hematopoietic Endothelial Cells, a unique stem cell therapy intended for BM/HSC transplant applications. Established in 2012, the company maintains its headquarters in London, United Kingdom.

Key Metrics
Market Cap$16.07M
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership--

based on 6.90M shares outstanding

SectorHealthcare
IndustryBiotechnology
ExchangeOTC
CountryGBGB
IPO Date-
Shares Outstanding6.90M
Authorized Shares
Float3.88M
52-Week Range
Volume
Average Daily Volume25.00K

30d Avg

25.00K

60d Avg

25.00K

90d Avg

25.00K

Earnings
Dividend History
No dividend history available